ONC · BeOne Medicines Ltd.
$365.94
+0.67 (+0.18%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$40.82B
Shares
113.12M
Volume · Sep 30
328.88K
Avg daily vol (3M)
388.06K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$365.94
Open$370.00
Day$365.79–376.50
52W close$260.27–377.47
Avg vol 30d365K
Short int1.7M · 1.5% float · 4.5d
Short vol49%
Last earningsAug 5, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 15, 2026
Est · unconfirmed
· in 6 wks
filed Aug 5, 2026
call held Feb 26, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+9.7%
Trailing year
Short interest
1.5%
Latest settlement · 4.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Moderate
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+14%
above
Price vs 50-day avg
+4%
above
RSI (14)
57
neutral
MACD trend
Positive
52-week position
90%
near high
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+2%
trailing
6-month return
+17%
trailing
YTD return
+20%
this year
Relative strength
+5%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $352 › 200d $320 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +45 funds added
Insider flow
Distributing
Net -$746.7K over 90 days · 100% sells
Short interest
Rising
1.51% of float · ▲ +20.0% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
283 holders — near 3-yr high, broad support
Squeeze score
63
elevated · 0–100
Fundamentals
Revenue growth
+22179%
Y/Y
Gross margin
1961%
contracting
EPS growth
+140%
Y/Y
Free cash flow
$941.7M
Valuation
P/E 820.1
rich
Balance sheet
$3.5B
net cash
Quant / Vol
risk profile
Volatility
35%
annualized · 1-yr
Max drawdown
−31%
past year
ATR
2.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 6, 2026
Total revenue
· Full Year 2026
Initiated
$6.3B – $6.5B
prior FY $5.34B
midpoint +19.8% Y/Y
GAAP operating expenses (combined R&D and SG&A)
· Full Year 2026
Initiated
$4.7B – $4.9B
GAAP operating income
· Full Year 2026
Initiated
$750M – $850M
Non-GAAP operating income
· Full Year 2026
Initiated
$1.45B – $1.55B
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+14%
Bullish
Price vs 50-day avg
+4%
Bullish
RSI (14)
57
Neutral
MACD trend
Positive
Bullish
52-week position
90%
Bullish
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $352 › 200d $320 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +45 funds added
Insider flow
Distributing
Net -$746.7K over 90 days · 100% sells
Short interest
Rising
1.51% of float · ▲ +20.0% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
283 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $260
Now $366 · 90%
Range high $377
vs 200-day avg +14%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ONC
this stock
BeOne Medicines Ltd.
|
$40.82B | +20.5% | +22179.2% | 820.1 | 1.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ONC | +0.3% | +2.0% | +16.8% | +1.8% | +20.5% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +0.9% | +1.9% | +4.6% | +2.4% | +8.6% |
Key facts
CIK
1651308
CUSIP
07725L102
13F (30d)
10 filings
8 filers
Visit website
Investor relations